期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

倍他乐克对心房颤动合并心衰患者运动时心率的影响

下载PDF
导出
摘要 目的 观察倍他乐克对心房颤动合并心衰患者运动时心率的作用和影响。方法 34例（治疗组）心房颤动合并心衰患者,在常规治疗（利尿剂,血管紧张素转换酶抑制剂,地高辛及抗凝治疗）基础上加用倍他乐克,开始剂量6.25-12.5 mg,2次/天,每7-10 d加量一倍,直至最大量25 mg或50mg,2次/天,并与30例常规治疗组（对照组）进行比较。结果 治疗组治疗3个月后静息和运动时心率均明显下降（P〈0.01）,且与对照组相比,运动时心率明显下降（P〈0.05）;心脏射血分数（EF）与治疗前及对照组比较明显升高（P〈0.05）。结论 倍他乐克能减低心房颤动合并心衰患者静息和运动时心率和改善心功能,安全方便,可作为首选的药物之一。
作者 赵甫 唐玉珍 王金娥
机构地区 安徽省宁国市华泰医院
出处 《安徽医药》 CAS 2007年第10期880-881,共2页 Anhui Medical and Pharmaceutical Journal
关键词 倍他乐克 心衰 心房颤动
分类号 R541.7 [医药卫生—心血管疾病] R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献6

  • 1兰永乔,曾朝荣.控制心律或控制心率——心房颤动治疗的两种策略[J].心血管病学进展,2005,26(5):471-474. 被引量：6
  • 2Wyse DG,Waldo Al,Dimarco JP,et al.A comparision of rate control and rhythm control in patients with a trial fibrillation[J].N Engl J M ed,2002,347:1825-1833.
  • 3Van Gelder IC Hagens VE Bosker HA,et al.A comparision of rate control and rhythm control in patients with recurrent persistent atrial fibrillation[J].NenglJ Med 2002,347:1834-40.
  • 4吕卓人,黄若文.神经内分泌拮抗剂在慢性心力衰竭治疗中的常见问题[J].中华心血管病杂志,2005,33(3):293-296. 被引量：24
  • 5Segal JB.McNamara RL,Miller MR et al.The evidence regarding the drugs used for ventricular rate control[J].J Fam Pract,2000,49:47-59.
  • 6Ang EL.chan wl,clebnd JGF,et al.placebo controlled trial of xamoterol versus digaoxin in chronic atrial fibrillation[J].Br Heart J,1990,64:256-60.

二级参考文献40

  • 1Lopez-Sendon J, Swedberg K, McMurray J, et al. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on β-adrenergic receptor blockers. Eur Heart J,2004,25:1341-1362.
  • 2Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J, 2004,25:1454-1470.
  • 3Packer M, Poole-Wilson PA, Armstrong PW, et al. On behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotension-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation,1999,100:2312-2318.
  • 4The NETWORK investigators. Clinical outcome with enalapril in systematic chronic heart failure, a dose comparison. Eur Heart J,1998,19:481-489.
  • 5Pitt B, Poole-Wilson PA, Segl R. On behalf of the ELITE II investigators Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet,2000,355:1582-1587.
  • 6Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity high -risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet,2002,360:752-760.
  • 7Pfeffer MA, McMurray JJ, Velasquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure. left ventricular dysfunction, or both. N Eng J Med,2003,349:1893-1906.
  • 8Mcmurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-ADDED trial. Lancet,2003,362:761-771.
  • 9Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet,1999,354:9-12.
  • 10Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-PreservedTrial. Lancet,2003,326:777-781.

共引文献28

安徽医药
2007年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部